Fate Therapeutics FATE
Fate Therapeutics FY 2020: revenue $31.4M; diluted EPS −$2.10
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-008086
- Document
- 10-K
- Exhibit 4.5
- Warrants or notes
- Exhibit 10.2
- Material contract
- Exhibit 10.7
- Material contract
- Exhibit 10.8
- Material contract
- Exhibit 10.9
- Material contract
- Exhibit 10.10
- Material contract
- Exhibit 10.19
- Material contract
- Exhibit 10.20
- Material contract
- Exhibit 10.21
- Material contract
- Exhibit 10.22
- Material contract
- Exhibit 10.39
- Material contract
- Exhibit 10.40
- Material contract
Key figures from this report
These are the numbers Fate Therapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$31.4MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$173.4MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$2.10No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$167.3MNo year-earlier figure tagged10-K balance sheet, on EDGAR
- Cash from operations−$39.2MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025
- Alector ALEC public float $115M, Jun 30, 2025